- •Despite high response rates with combination immunotherapy, many later progress.
- •Aside from BRAF/MEKi, there are no standard subsequent therapies available.
- •The role of reinduction with ipilimumab (alone or in combination) is unclear.
- •The response rate to reinduction was 26%, and the disease control rate was 45%.
- •38% had grade 3/4 toxicity, but only 40% of induction toxicities recurred.
Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown.
Patients with advanced melanoma who initially achieved a complete response, partial response or sustained stable disease to induction combination immunotherapy then progressed and were reinduced with ipilimumab (alone or in combination with anti–PD-1) and were analysed retrospectively. Demographics, disease characteristics, efficacy and toxicity were examined.
Forty-seven patients were identified from 12 centres. The response rate to reinduction therapy was 12/47 (26%), and disease control rate was 21/47 (45%). Responses appeared more frequent in patients who developed AR after ceasing induction immunotherapy (30% vs. 18%, P = 0.655). Time to AR was 11 months (95% confidence interval [CI], 8–15 months). After a median follow-up of 16 months (95% CI, 10–25 months), responders to reinduction had a median progression-free survival of 14 months (95% CI, 13, NR months), and in the whole cohort, the median overall survival from reinduction was 17 months (95% CI, 12–NR months). Twenty-seven (58%) immune-related adverse events (irAEs) were reported; 18 (38%) were grade 3/4, and in 11 of 27 (40%), the same irAE observed during induction therapy recurred.
Reinduction with ipilimumab ± anti–PD-1 has modest clinical activity. Clinicians should be attentive to the risk of irAEs, including recurrence of irAEs that occurred during induction therapy. Future studies are necessary to determine best management after resistance to combination immunotherapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med. 2019; https://doi.org/10.1056/nejmoa1910836
- Characteristics of long-term survivors and subgroup analyses with combination nivolumab plus ipilimumab for advanced melanoma (CheckMate 067).in: X Presented at: 16th international congress of the society for melanoma research; November 20-23. X, 2019 (Salt Lake City, UT)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol. 2014; 32https://doi.org/10.1200/JCO.2013.53.0105
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol. 2019; 4: 1-13https://doi.org/10.1016/S1470-2045(19)30388-2
- Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.Cancer. 2019; 125: 884-891https://doi.org/10.1002/cncr.31889
- Cancer therapy: clinical efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.Clin Cancer Res. 2013; 19https://doi.org/10.1158/1078-0432.CCR-12-3080
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.Ann Oncol. 2014; 25: 2277-2284https://doi.org/10.1093/annonc/mdu441
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247https://doi.org/10.1016/j.ejca.2008.10.026
- Common terminology criteria for adverse events (CTCAE) version 5.0.US Dep Heal Hum Serv, 2017: 1-146
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Br J Cancer. 2014; 110https://doi.org/10.1038/bjc.2014.126
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.Ann Oncol. 2019; 30: 1154-1161https://doi.org/10.1093/annonc/mdz110
- Long-Term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade.J Clin Oncol. 2020; https://doi.org/10.1200/JCO.19
- Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.in: Presented at:2020 ASCO virtual annual meeting. 2020
- Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.in: Presented at:2020 ASCO Virtual Annual Meeting. 2020
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.Lancet Oncol. 2017; 18: 1202-1210https://doi.org/10.1016/S1470-2045(17)30428-X
- Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma.N Engl J Med. 2015; 373: 23-34https://doi.org/10.1056/NEJMoa1504030
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 1480-1492https://doi.org/10.1016/S1470-2045(18)30700-9
Published online: June 29, 2021
Accepted: April 16, 2021
Received in revised form: March 24, 2021
Received: December 11, 2020
This study was presented in part at the European Society of Medical Oncology Congress 2019 in Barcelona.
© 2021 Elsevier Ltd. All rights reserved.